Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3154

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Alzheimer's Disease
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 127
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 107 more

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 31 Years
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more

Conditions: Cardiac Arrest, Cardiopulmonary Arrest
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 0 Years to 18 Years
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 42
States / cities: Los Angeles, California • Madera, California • Orange, California + 33 more

Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Interventions: DUO Transcatheter Tricuspid Coaptation Valve System; Device
Lead sponsor: CroiValve Limited; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: Phoenix, Arizona • Thousand Oaks, California • Atlanta, Georgia + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive, Emphysema, Bronchitis, Chronic
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years to 80 Years
Enrollment: 10,718 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 14 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 34
States / cities: Colorado Springs, Colorado • Kissimmee, Florida • Miami, Florida + 26 more

Conditions: Von Hippel-Lindau Disease, Malignant Neoplasms
Interventions: Belzutifan, Nivolumab, Lenvatinib, Cabozantinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 8
States / cities: Boston, Massachusetts • Detroit, Michigan • Philadelphia, Pennsylvania + 4 more

Conditions: Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
Interventions: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Radiation Therapy, Thioguanine, Vincristine, Vincristine Sulfate; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 188
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more

Conditions: Advanced Solid Tumors, Colorectal Cancer
Interventions: VVD-133214, Pembrolizumab, Bevacizumab; Drug
Lead sponsor: Vividion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 18
States / cities: Tucson, Arizona • Duarte, California • Irvine, California + 14 more

Conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions: Remigromig, Aflibercept 2.0 mg; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more

Conditions: Papillomavirus Infections
Interventions: 9vHPV Vaccine, Placebo (Saline for Injection); Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 6,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Northridge, California • Rialto, California • Simi Valley, California + 28 more

Clinical trials in San Antonio, Texas

Filter and sort this location

Live official records

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Quality of Pediatric Resuscitation in a Multicenter Collaborative

EFS of the DUO System for Tricuspid Regurgitation

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)